Boeing vs Honeywell vs 3M: Which Dip Is the Best Buy Right Now?

Boeing reported Q4 revenue of $23.95B (+57% YoY) and headline EPS $9.92 driven by a $9.67B divestiture gain; excluding that, Commercial Airplanes and Defense operating margins were −5.6% and −6.8%, full‑year free cash flow was −$1.877B and consolidated debt $54.1B, shares down 12.9% to ~$200 (consensus target $272.25, forward P/E ~137x). 3M shares fell 11.2% to ~$147 despite operational improvement — Q4 adjusted operating margin rose 140bps to 21.1%, Q4 GAAP EPS $1.07 vs adjusted $1.83, PFAS net pre-tax cash payments totaled $3.5B in 2025 and 2026 net FCF guidance is $4.6–$4.8B (forward P/E 17x, target $178.73). Honeywell is the least pulled back (−7% to ~$226), with 21% organic Aerospace sales growth, backlog >$37B and a planned aerospace/automation separation in Q3 2026, limiting near-term upside versus its $251.44 analyst target.

Analysis

The mid‑cycle drawdowns are exposing two different investor errors: one group is conflating headline accounting noise with durable cash returns, the other is pricing legal uncertainty as permanent impairment. That distinction matters because recoveries in aftermarket/defense cash conversion and remediation visibility resolve on different cadences and through different mechanisms (contract conversion, reserve releases, settlement milestones), so time arbitrage matters as much as valuation arbitrage.

Second‑order beneficiaries include smaller MRO and parts suppliers that sit downstream of each OEM — if Boeing’s execution delays persist, independent MROs capture incremental service revenue, while a cleaner liability path at 3M funnels more free cash to buybacks/dividends rather than capex, supporting suppliers of industrial adhesives and specialty chemicals. Conversely, management bandwidth diverted into litigation or turnarounds raises implementation risk for corporate actions (spin, divestiture) at peers, increasing governance arbitrage opportunities.

Key risks and near‑term catalysts are distinct: legal settlement quantum and milestone cadence drive binary moves for companies facing legacy liabilities, whereas for turnaround stories the next 2–4 quarterly cash flow prints and backlog conversion rates drive re‑rating. Macro and defense windows (contract awards, OEM cadence) create episodic volatility — these are the points to trade around rather than buy-and‑hold blind.

Consensus underestimates optionality in aftermarket cash conversion and overestimates permanency of headline GAAP hits. That creates asymmetric payoff structures we can harvest with directional option structures and pairs that neutralize macro/industry cyclicality while exposing idiosyncratic rehypothecation of cash to capital returns.

Key Decisions for Investors

• Long MMM via a calendar/vertical call spread: buy Jan‑2027 140–175 call spread (debit) sized 1–2% NAV; target 40–60% upside by Jan‑2027 if litigation cadence remains predictable. Hedge tail risk by buying a 12–18 month out‑of‑the‑money put (smaller notional) to cap settlement shock losses to ~20% of position.
• Asymmetric Boeing exposure with defined risk: buy Mar‑2027 1x2 call spread (long lower strike, short 2x higher strike) sized 0.5–1% NAV to play upside from backlog conversion, funded by selling near‑dated calls against a separate small long position. Cut exposure if two consecutive quarters show negative consolidated free cash flow or net leverage fails to decline.
• Relative value pair — long MMM / short HON equal notional industrial exposure for 6–12 months (size 1–3% NAV): isolates litigation resolution vs valuation compression on corporate‑action fatigue. Take profits if spread compresses by 50% or if HON announces a material change to separation timeline.
• Avoid outright long on HON pre‑separation; instead sell a modest amount of short‑dated call premium against a long equity base (covered calls) to monetize limited upside while keeping equity exposure. Unwind if separation timeline accelerates materially or if guidance upgrades reset consensus targets.